COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 2622: Articles 26211-26220  | Next

On Identifying and Mitigating Bias in the Estimation of the COVID-19 Case Fatality Rate
Angelopoulos, A. N., Pathak, R., Varma, R., Jordan, M. I.
10.1101/2020.06.15.20038489 — Posted: 2020-06-19 Discussion: Onsite
A longitudinal study of immune cells in severe COVID-19 patients.
Payen, D., Cravat, M., Maadadi, H., Didelot, C., Prosic, L., Dupuis, C., Losser, M.-R., De Carvalho Bittencourt, M.
10.1101/2020.06.16.20130914 — Posted: 2020-06-19 Discussion: Onsite
Potential involvement of monoamine oxidase activity in SARS-COV2 infection and delirium onset
Cuperlovic-Culf, M., Cunningham, E. L., Surendra, A., Pan, X., Bennett, S. A. L., Jung, M., McGuiness, B., Passmore, A. P., McAuley, D., Beverland, D., Green, B. D.
10.1101/2020.06.16.20128660 — Posted: 2020-06-19
Does Gender or Religion Contribute to the Risk of COVID-19 in Hospital Doctors?
Daga, S., Jafferbhoy, S., Menon, G., Ali, M., Chakravorty, S., Ghani, S., Burney, A., Bamrah, J., Mehta, R., Chakravorty, I.
10.1101/2020.06.15.20125450 — Posted: 2020-06-19
Variant analysis of SARS-CoV-2 strains in Middle Eastern countries
Bindayna, K. M., Crinion, S.
10.1101/2020.06.18.156810 — Posted: 2020-06-18
Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
Mulgaonkar, N. S., Wang, H., Mallawarachchi, S., Ruzek, D., Martina, B., Fernando, S.
10.1101/2020.06.18.158196 — Posted: 2020-06-18
Polymorphism and selection pressure of SARS-CoV-2 vaccine and diagnostic antigens: implications for immune evasion and serologic diagnostic performance
Dumonteil, E., Herrera, C.
10.1101/2020.06.18.158329 — Posted: 2020-06-18
Early temporal dynamics of cellular responses to SARS-CoV-2
Banerjee, A., Budylowski, P., Richard, D., Maan, H., Aguiar, J., El-Sayes, N., D'Agostino, M. R., Tremblay, B. J.- M., Afkhami, S., Karimzadeh, M., Yip, L., Ostrowski, M. A., Hirota, J. A., Kozak, R., Capellini, T. D., Miller, M. S., McArthur, A. G., Wang, B., Doxey, A. C., Mubareka, S., Mossman, K.
10.1101/2020.06.18.158154 — Posted: 2020-06-18 Discussion: Onsite | Offsite
Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs
Kern, D. M., Sorum, B., Hoel, C. M., Sridharan, S., Remis, J. P., Toso, D. B., Brohawn, S. G.
10.1101/2020.06.17.156554 — Posted: 2020-06-18 Discussion: Onsite | Offsite
Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19
Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A., Cuvalay, S., Slot, E., Swaneveld, F. H., Vrielink, H., Rispens, T., van der Schoot, E., van Lier, R. A. W., Ten Brinke, A., Hombrink, P.
10.1101/2020.06.18.159202 — Posted: 2020-06-18 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).